Načítá se...
Brief report: EGFR L858M/L861Q cis mutations confer selective sensitivity to afatinib
INTRODUCTION: Tyrosine kinase inhibitors (TKIs) have been developed to treat patients with epidermal growth factor receptor (EGFR)-mutant lung cancers. However, the therapeutic efficacy of TKIs in patients with uncommon EGFR mutations remains unclear. METHODS: Next-generation sequencing was performe...
Uloženo v:
| Vydáno v: | J Thorac Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5558893/ https://ncbi.nlm.nih.gov/pubmed/28088511 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2017.01.006 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|